JP2024516998A5 - - Google Patents
Info
- Publication number
- JP2024516998A5 JP2024516998A5 JP2023567923A JP2023567923A JP2024516998A5 JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5 JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- inhibitor
- cycloalkyl
- egfr
- alkylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184697P | 2021-05-05 | 2021-05-05 | |
| US63/184,697 | 2021-05-05 | ||
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| US63/320,991 | 2022-03-17 | ||
| PCT/US2022/027693 WO2022235815A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516998A JP2024516998A (ja) | 2024-04-18 |
| JP2024516998A5 true JP2024516998A5 (cg-RX-API-DMAC10.html) | 2025-05-14 |
Family
ID=83932546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567923A Pending JP2024516998A (ja) | 2021-05-05 | 2022-05-04 | Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220370456A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4334317A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024516998A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022270106A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3217092A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL308225A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023012929A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022235815A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| WO2015050345A1 (en) | 2013-10-01 | 2015-04-09 | Lg Electronics Inc. | Control apparatus for mobile terminal and control method thereof |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| CN110730678B (zh) * | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| CN117263942A (zh) * | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) * | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2022235822A1 (en) * | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
| CA3217084A1 (en) * | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
-
2022
- 2022-05-04 MX MX2023012929A patent/MX2023012929A/es unknown
- 2022-05-04 JP JP2023567923A patent/JP2024516998A/ja active Pending
- 2022-05-04 AU AU2022270106A patent/AU2022270106A1/en active Pending
- 2022-05-04 IL IL308225A patent/IL308225A/en unknown
- 2022-05-04 WO PCT/US2022/027693 patent/WO2022235815A1/en not_active Ceased
- 2022-05-04 US US17/736,869 patent/US20220370456A1/en active Pending
- 2022-05-04 EP EP22799518.0A patent/EP4334317A4/en active Pending
- 2022-05-04 CA CA3217092A patent/CA3217092A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516997A5 (cg-RX-API-DMAC10.html) | ||
| AU2009279771B2 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| TWI833055B (zh) | 抗癌化合物及其醫藥用途 | |
| JP2018504418A5 (cg-RX-API-DMAC10.html) | ||
| EP2591805A1 (en) | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
| JP2020536971A5 (cg-RX-API-DMAC10.html) | ||
| CN114364677A (zh) | 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物 | |
| US20250262214A1 (en) | Intermittent dosing regimen for azenosertib in treating cancer | |
| JPWO2020032105A5 (cg-RX-API-DMAC10.html) | ||
| JP2024125139A5 (cg-RX-API-DMAC10.html) | ||
| JP2024516037A5 (cg-RX-API-DMAC10.html) | ||
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| JP2024515061A5 (cg-RX-API-DMAC10.html) | ||
| JP2026506975A (ja) | 薬物コンジュゲートの腫瘍疾患治療における使用および方法 | |
| JP2022550040A5 (cg-RX-API-DMAC10.html) | ||
| CN101175495B (zh) | 抗癌化合物的组合 | |
| CN1879619A (zh) | 癌症治疗 | |
| TW202604574A (zh) | 抗體藥物偶聯物在預防或治療疾病中的應用 | |
| WO2023212181A1 (en) | Compounds for proliferative disorders | |
| JP6553726B2 (ja) | 腫瘍治療剤 | |
| HK40113079A (en) | Antineoplastic combinations of neratinib and capecitabine | |
| JP2023511039A (ja) | 組み合わせ療法 | |
| HK40072488A (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists | |
| RU2020138336A (ru) | Ингибиторы рецепторов erbb | |
| HK1239521A1 (en) | Antineoplastic combinations of neratinib and capecitabine |